Monopar Therapeutics (MNPR) Cash & Equivalents (2016 - 2025)

Monopar Therapeutics has disclosed Cash & Equivalents across 10 years of filings, most recently posting $61.8 million for Q4 2025.

• Cash & Equivalents for Q4 2025 came in at $61.8 million, up 34.96% year-over-year; the trailing twelve-month figure through Dec 2025 was $61.8 million (up 34.96% YoY), and the FY2025 annual result was $61.8 million, up 34.96% from the prior year.
• Cash & Equivalents came in at $61.8 million for Q4 2025 at Monopar Therapeutics, down from $127.7 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $127.7 million in Q3 2025 to a low of $5.5 million in Q3 2023.
• The 5-year median for Cash & Equivalents is $17.1 million (2022), against an average of $25.4 million.
• Across the five-year window, Cash & Equivalents plunged 67.87% in 2023 and soared 2020.86% in 2025, its largest moves.
• Monopar Therapeutics' Cash & Equivalents stood at $20.0 million in 2021, then plunged by 59.1% to $8.2 million in 2022, then fell by 11.24% to $7.3 million in 2023, then jumped by 530.55% to $45.8 million in 2024, then jumped by 34.96% to $61.8 million in 2025.
• The last three Cash & Equivalents figures came in at $61.8 million (Q4 2025), $127.7 million (Q3 2025), and $39.5 million (Q2 2025), per Business Quant data.